Evidence map›Paper›PMID 40196662›Full record

ArticlebioRxiv : the preprint server for biology2025

U2AF1 mutations rescue deleterious exon skipping induced by KRAS mutations.

David M Walter, Katherine Cho, Smruthy Sivakumar, Daniel Denney, Iris T-H Lee, Anders B Dohlman, Jakob M Heinz, Ethan Shurberg, Kevin X Jiang, Akansha A Gupta and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

David M WalterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Katherine ChoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Smruthy SivakumarFoundation Medicine Inc., Boston, MA.
Daniel DenneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Iris T-H LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Anders B DohlmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jakob M HeinzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Ethan ShurbergDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Kevin X JiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Akansha A GuptaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Garrett M FramptonFoundation Medicine Inc., Boston, MA.
Matthew MeyersonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Funding

NKX2-1 Enhancer Amplification and Lineage Addiction in Lung AdenocarcinomaR35CA197568 · NCI · DANA-FARBER CANCER INST · PI Matthew L. Meyerson · 2015 to 2026
$12.4M
NCI NIH HHS R35 CA197568
6 · The paper itself

Abstract

The mechanisms by which somatic mutations of splicing factors, such as U2AF1

Identifiers

PMID40196662
PMCPMC11974705

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.